Kerns Laboratory
Location
MFRC 6009 (Lab)
MFRC 6010 (Office)
Research Areas
The Kerns lab studies inherited genetic predisposition to development of late toxicities resulting from cancer treatment. Approaches include genome-wide association studies (GWAS), analysis of circulating biomarkers, and analysis of gene expression and epigenetic changes using biospecimens from patients undergoing treatment for cancer. The long-term goal of our research is to develop predictive models for use in the clinic to better personalize cancer treatment and survivorship care. Research conducted in the lab also aims to uncover novel biologic pathways that might be targeted to prevent or mitigate the toxic effects of cancer treatment. Much of this work is done collaboratively, through research consortia, to facilitate large-scale clinical genomic studies. Dr. Kerns is a leader in the NCI-supported International Radiogenomics Consortium and a member of the NIH-funded Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium.
Current Members

Carson Gehl, BS
Data Specialist I



Lauren Smith, BS
Data Specialist I
MCW Collaborators

William A. Hall, MD
Professor of Radiation Oncology and Surgery, School of Graduate Studies; Medical Director of Radiation Oncology, Froedtert & the Medical College of Wisconsin Clinical Cancer Center
Clinical and research interests include pancreatic cancer, prostate cancer, MRI guided radiation therapy, renal cell carcinoma and rectal cancer.

Paul Auer, PhD
Cancer Center Scholar; Director, Biostatistics Shared Resource, Cancer Center; Professor, Data Science Institute, Biostatistics

Kerns Laboratory Funding

Recent Publications
-
BIOLOGICAL INDIVIDUALIZATION OF RADIOTHERAPY
(West CML, Marignol L, Kerns SL.) Basic Clinical Radiobiology, Sixth Edition. 1 January 2025:237-249 SCOPUS ID: 2-s2.0-85212733615 01/01/2025
-
(Bouzaki A, Green D, van Herk M, Shortall J, Puri T, Kerns S, Azria D, Farcy-Jacquet MP, Chang-Claude J, Choudhury A, Dunning A, Lambrecht M, Avuzzi B, Ruysscher DD, Seibold P, Sperk E, Talbot C, Vega A, Veldeman L, Webb A, Rosenstein B, West CM, Gioscio E, Rancati T, Osorio EV, McWilliam A.) Physics and Imaging in Radiation Oncology. January 2025;33 SCOPUS ID: 2-s2.0-85215853089 01/01/2025
-
The PRIMED Consortium: Reducing disparities in polygenic risk assessment.
(Kullo IJ, Conomos MP, Nelson SC, Adebamowo SN, Choudhury A, Conti D, Fullerton SM, Gogarten SM, Heavner B, Hornsby WE, Kenny EE, Khan A, Khera AV, Li Y, Martin I, Mercader JM, Ng M, Raffield LM, Reiner A, Rowley R, Schaid D, Stilp A, Wiley K, Wilson R, Witte JS, Natarajan P, Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium.) Am J Hum Genet. 2024 Dec 05;111(12):2594-2606 PMID: 39561770 PMCID: PMC11639095 SCOPUS ID: 2-s2.0-85210411516 11/20/2024
-
(Gehl CJ, Verhagen NB, Shaik TJ, Nimmer K, Yang X, Xing Y, Taylor BW, Nataliansyah MM, Kerns SL, Kothari AN.) J Am Coll Surg. 2024 Dec 01;239(6):539-546 PMID: 38920308 SCOPUS ID: 2-s2.0-85216036137 06/26/2024
-
The Need to Enrich Population Diversity in Radiogenomic Research.
(Rosenstein BS, Yamoah K, Bentzen SM, Kerns SL, McDonald JT, West CML, Vega A, Rattay T, Ricks-Santi LJ, Radiogenomics Consortium.) Int J Radiat Oncol Biol Phys. 2024 Nov 15;120(4):1107-1110 PMID: 39424580 SCOPUS ID: 2-s2.0-85206214409 10/19/2024
-
(Hall WA, Mathison AJ, DeVoe E, Tschannen M, Wendt-Andrae J, Straza M, Awan M, Puckett LL, Lawton CAF, Schultz C, Urrutia R, Kerns S, Torres-Roca JF, Li XA, Erickson B, Nevalainen MT, Zimmermann MT, Paulson E.) Int J Radiat Oncol Biol Phys. 2024 Oct 01;120(2):570-578 PMID: 38819340 SCOPUS ID: 2-s2.0-85194948255 05/31/2024
-
Association between rheumatoid arthritis and risk of radiotherapy toxicity: a systematic review.
(Liebenberg N, McWilliam A, Kerns SL, Marshall DC, West CM.) BMJ Oncol. 2024 Jan;3(1) PMID: 39524982 PMCID: PMC11256021 11/14/2024
-
(Cui W, Plett PA, Sharma GP, Kerns S, MacVittie TJ.) Front Public Health. 2024;12:1471228 PMID: 39234079 PMCID: PMC11372479 SCOPUS ID: 2-s2.0-85203343450 09/05/2024